Enyo Pharma

Enyo Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH). Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor.

Company Details

Employees
38
Founded
-
Address
60 Avenue Rockefeller, 69008 Lyon, France, Bioserra 1,bâtiment B,france
Phone
33437700219
Email
co****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Lyon, Rhône-Alpes
Looking for a particular Enyo Pharma employee's phone or email?

Enyo Pharma Questions

News

ENYO Pharma Announces Completion of Series C Financing With Vesalius Biocapital and Continued Progress of Its ALPESTRIA-1 Clinical Phase 2 Study in Alport Syndrome Patients - Business Wire

ENYO Pharma Announces Completion of Series C Financing With Vesalius Biocapital and Continued Progress of Its ALPESTRIA-1 Clinical Phase 2 Study in Alport Syndrome Patients Business Wire

ENYO Pharma provides updates on vonafexor for the treatment of hepatitis B - European AIDS Treatment Group

ENYO Pharma provides updates on vonafexor for the treatment of hepatitis B European AIDS Treatment Group

ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome - BioSpace

ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome BioSpace

ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome - Business Wire

ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome Business Wire

Top Enyo Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant